1369773-39-6

基本信息
沙庫(kù)巴曲鈣
沙庫(kù)必曲鈣鹽
沙庫(kù)巴曲鈣鹽
LCZ中間體
沙庫(kù)比曲鈣鹽
HU377鈣鹽
AHU377鈣鹽
原研534-06
LCZ696雜質(zhì)P
LCZ696-1
Sacubitril Calcium
AHU377 Calcium Salt
AHU-377 Hemicalcium
LCZ696 Impurity 534-06
Sacubitril calcium salt
AHU-377 (heMicalciuM salt)
Sacubitril Hemicalcium salt
AHU-377 hemicalcium salt (2:1)
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問題列表
沙必利是一種與纈沙坦聯(lián)合使用的降壓藥。這種名為纈沙坦/沙必利的聯(lián)合藥物在試驗(yàn)中被稱為L(zhǎng)CZ696,并以Entresto品牌銷售,是一種治療心力衰竭的藥物。本品用作該藥物中間體和雜質(zhì)對(duì)照品,用于藥品申報(bào)檢測(cè)等。
IC50: 5 nM (NEP)
Sacubitril (AHU-377) is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and Sacubitril hemicalcium salt, a neprilysin inhibitor (1:1 ratio). Sacubitril (AHU-377) is converted by enzymatic cleavage of the ethyl ester into the active neprilysin inhibiting metabolite LBQ657. The inactive NEPi precursor, Sacubitril hemicalcium salt, does not inhibit collagen accumulation in fibroblasts nor cardiac myocyte hypertrophy. In cardiac fibroblasts, the active NEPi LBQ657 had no discernible effects. In contrast, LBQ657 modestly inhibits cardiac myocyte hypertrophy.
In humans, Sacubitril (AHU-377)(t max 0.5-1.1 h) are absorbed quickly. Sacubitril hemicalcium salt is converted rapidly into LBQ657 with its t max being reached in 1.9-3.5 h. Mean t 1/2 values for the biologically active LBQ657 is 9.9-11.1 h.In vehicle-treated dogs, ANF increases urinary sodium excretion from 17.3±3.6 to 199.5±18.4 pequivkglmin. This effect is potentiated significantly in animals which receive Sacubitril (AHU-377). Urinary volume is also potentiated in animals which receive an iv administration of Sacubitril (AHU-377).
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
2025/02/08 | HY-15407A | LCZ696中間體 Sacubitril hemicalcium salt | 1369773-39-6 | 2mg | 410元 |
2025/02/08 | HY-15407A | LCZ696中間體 Sacubitril hemicalcium salt | 1369773-39-6 | 10mM * 1mLin DMSO | 603元 |
2025/02/08 | HY-15407A | LCZ696中間體 Sacubitril hemicalcium salt | 1369773-39-6 | 5mg | 637元 |